Shanghai Factory

Efficient construction of a production base that meets international standards is expected to become the world's first atherosclerosis targeted drug commercial production plant and the world's largest single batch liposome production line

Inno Medicine has established the world's first known atherosclerotic targeted drug production line in Waigaoqiao, Shanghai Inno. The factory construction started in November 2022, and the completion acceptance was officially passed in September 2023. The building area exceeds 15000 square meters, and the design, construction, and operation comply with international standards. Shanghai Inno, as the first production base of Inno Medicine, not only achieves independent production of Inno clinical trial drugs, but also prepares technical reserves and production capacity for commercial production and global supply of drugs after approval for marketing. It also marks the successful establishment of Inno Medicine' R&D and production technology platform for targeted liposome drugs from demonstration and project approval, concept validation, process development, clinical research, to industrialization.